My friends in the Dementia world. Please read this and consider what the effects on healthcare for people with Alzheimer’s disease in England would have been if NICE had approved lecanemab and donanemab for NHS use. And, of course, they don’t have clinical efficacy, anyway!
Reposted from
Seb Walsh
Amazing paper in @thelancet.bsky.social evidencing something we argue in #publichealth the whole time: the opportunity cost of increasingly expensive medications
'During 2000–20, NHS coverage of new drugs displaced more population health than it generated.'
www.thelancet.com/journals/lan...
'During 2000–20, NHS coverage of new drugs displaced more population health than it generated.'
www.thelancet.com/journals/lan...
Comments
Also - great point as usual.